Zimmer Biomet EEC – subject to conditions


European Commission – Press release

Mergers: Commission approves acquisition of orthopaedic implants producer Biomet by Zimmer, subject to conditions

Brussels, 30 March 2015

The European Commission has approved under the EU Merger Regulation the proposed acquisition of Biomet Inc by Zimmer Holdings Inc., both of the United States. Both companies produce orthopaedic implants and related surgical products. The approval is conditional upon a commitments package submitted by Zimmer. The Commission had concerns that the merger, as initially notified, could have resulted in price increases for a number of orthopaedic implants in the European Economic Area (EEA). The commitments offered by Zimmer remove these concerns.

“Orthopaedic implants affect the mobility and quality of life of thousands of people across Europe.The remedies obtained by the Commission will ensure that patients continue to benefit from sufficient choice and innovation and that healthcare providers enjoy competitive prices.” said Margrethe Vestager, Commissioner in charge of competition policy.

The Commission assessed the proposed transaction’s effect on competition in particular in the markets for:

(a) partial (unicondylar) knee implants in Austria, Belgium (including sales in Luxembourg), the Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, The Netherlands, Poland, Portugal, Slovenia, Spain, Sweden and the UK;

(b) elbow implants in Austria, Belgium (including sales in Luxembourg), the Czech Republic, Denmark, France, Germany, Italy, Norway, Portugal, Spain, Sweden and the UK; and

(c) total knee implants in Denmark (primary and revision) and Sweden (primary).

On these markets, the merged entity would have faced insufficient competitive constraint from the remaining players, which are much smaller. In addition, barriers to entry are relatively high. Thus, the merger would have led to less innovation and choice, as well as to price increases for the products concerned.

To address these concerns, Zimmer offered to divest the Zimmer Unicondylar Knee implant(“ZUK”) and Biomet’s Discovery Elbow (“Discovery”), both across the EEA, and the Biomet Vanguard total Knee system for primary and revision implants (“Vanguard Knee”) in Denmark and Sweden. In addition, Zimmer committed to grant to the purchaser of the Vanguard knee in Denmark and Sweden an EEA-wide, non-exclusive license to the rights and know-how that are currently used and are needed for the manufacturing, marketing and sale of an exact copy of the Vanguard Knee.

The three divestment businesses include instrumentation, any improvements and pipeline projects. The divestments also include intellectual property rights and know-how; the transfer of licences, permits and authorisations; the transfer of access toCE marks (the certification that allows a medical device to be sold in the EEA); customer contracts, leases, commitments, orders and records; key personnel, technical assistance and training. Furthermore, Zimmer committed for a transitional period to supply the divestment businesses’ product lines at reasonable conditions.

The remedy ensures that the purchasers of the ZUK and the Discovery will acquire the positions that Zimmer and Biomet currently hold in the unicondylar knee and elbow implants markets, respectively. The Vanguard Knee remedy will transfer the largest part of Biomet’s market share to a competitor.

A set of additional purchaser criteria will ensure that these assets are sold to one or several purchasers capable of running the businesses as a competitive force in the market. In addition, the companies committed not to implement the transaction beforeone or more suitable purchasers are found and approved by the Commission for all of the divested businesses.

The Commission concluded that the transaction, as modified by the commitments, would no longer raise competition concerns. This decision is conditional upon full compliance with the commitments.


The Commission has already adopted other decisions under the Merger Regulation concerning the orthopaedic implants industry. In particular, in April 2012the Commission approved the the acquisition of Synthes by Johnson & Johnson, subject to conditions.

Zimmer notified its proposed acquisition of Biomet to the Commission in June 2014. After the Commission found the notification incomplete, Zimmer submitted a revised notification in July 2014 and subsequently additional information. The notification became effective as of 29 August 2014. The Commission opened an in-depth investigationin October 2014. Throughout the proceedings the Commission cooperated closely with the US Federal Trade Commission and the Japanese Fair Trade Commission.


Zimmer Holdings Inc is a US publicly traded company. Its common stock is traded on the New York Stock Exchange and the SIX Swiss Exchange. Zimmer is active in the design, development, manufacture and marketing of orthopaedics, reconstructive, spinal and trauma devices, biologics, dental implants and related surgical products.

Biomet Inc is a wholly owned subsidiary of LVB, a holding company whose shares are not publicly traded. Biomet is active in orthopaedic and other medical devices and related products.

Merger rules and procedures

The Commission has the duty to assess mergers and acquisitions involving companies with a turnover above certain thresholds (see Article 1 of the Merger Regulation) and to prevent concentrations that would significantly impede effective competition in the EEA or any substantial part of it.

The vast majority of notified mergers do not pose competition problems and are cleared after a routine review. From the moment a transaction is notified, the Commission generally has a total of 25 working days to decide whether to grant approval (phase I) or to start an in-depth investigation (phase II).

There are currently seven other ongoing phase II investigations:

-     the proposed joint venture between two of world’s leading coffee manufacturers, Douwe Egberts Master Blenders 1753 B.V. (DEMB) of the Netherlands and Mondelēz International Inc. (Mondelēz) of the US, with a decision deadline on 1 June 2015 (IP/14/2682);

-     the proposed creation of a joint venture between the collective rights management organisations PRSfM of the UK, STIM of Sweden and GEMA of Germany in the online licensing of musical works, with a decision deadline on 26 June 2015 (IP/15/3300);

-     the proposed acquisition of the industrial chocolate business of Archer Daniels Midland by Cargill, with a decision deadline on 23 July 2015 (IP/15/4479);

-     General Electric’s proposed acquisition of the thermal power, renewable power & grid businesses of Alstom, with a decision deadline on 6 August 2015 (IP/15/4478);

-     the proposed acquisition of the Greek gas transmission system operator DESFA by the State Oil Company of Azerbaijan Republic (SOCAR) (IP/14/1442);

-     the proposed acquisition of telecommunications company Jazztel by rival Orange (IP/14/2367and IP/15/3680); and

-     the proposed acquisition of rotating equipment manufacturer Dresser-Rand of the US by Siemens of Germany (IP/15/4429).

More information on this case is available on the Commission’s competition website, in the publiccase register under the case number M.7265.


Press contacts

  • Ricardo CARDOSO (+32 2 298 01 00)
  • Carolina LUNA GORDO (+32 2 296 83 86)

General public inquiries:

  • Europe Direct by phone 00 800 67 89 10 11 or by email

Comments are closed.